

## Supplemental Material

Table S1: Viral load measurements for RT-SHIV+ NHPs

NHP ID	Sex	Drug regimen	Day* of peak pVL	Peak pVL (copies/mL)	Day* of ART start	Art start pVL (copies/mL)	MLN VL at necropsy (copies/10 <sup>6</sup> cells)	pVL at necropsy (copies/mL)
42226	M	FTER	21	250,000	42	28,000	7,529	7.5
42971	M	FTER	21	1,500,000	42	97,000	2,736	380
40437	M	FTER	14	6,900,000	42	1,100,000	50,458	1,900
42707	F	FTER	14	16,000,000	42	190,000	193,323	340
40422	F	FTER	21	1,200,000	42	130,000	109,035	3,800
42827	M	FTMA	14	9,800,000	42	130,000	27,940	1,100
41380	M	FTMA	14	60,000,000	42	3,000,000	5,416,860	68,000
42966	M	FTMA	14	11,000,000	42	4,400,000	940,280	19,000
42350	F	FTMA	14	13,000,000	42	150,000	17,167	2,200
42706	F	FTMA	14	17,000,000	42	2,400,000	302,243	30,000

Table S2: Physicochemical properties of ARVs

ARV	Molecular weight (g/mol)	Lipophilicity (LogP)	Solubility (mg/mL)
FTC	247.25	-0.43	112
TFV	287.21	-1.6	13.4
EFV	315.67	4.6	0.00855
RAL	445.16	0.5	4.45
MVC	513.7	5.1	0.0106
ATV	704.9	5.6	0.0001

Figure S1




Figure S1: ARV concentrations in four different lymph node types. Bars are median, and error bars are 25<sup>th</sup> and 75<sup>th</sup> percentile.